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HbA1c below 7 % as the goal of glucose 
control fails to maximize the cardiovascular 
benefits: a meta-analysis
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Abstract 
Objective: Whether lowering glycosylated haemoglobin (HbA1c) level below 7.0 % improves macro-vascular out-
comes in diabetes remains unclear. Here, we aimed to assess the effect of relatively tight glucose control resulting in a 
follow-up HbA1c level of less or more than 7.0 % on cardiovascular outcomes in diabetic patients.
Research design and methods: We systematically searched Medline, Web of science and Cochrane Library for 
prospective randomized controlled trials published between Jan 1, 1996 and July 1, 2015 that recorded cardiovascular 
outcome trials of glucose-lowering drugs or strategies in patients with type 2 diabetes mellitus.
Results: Data from 15 studies involving 88,266 diabetic patients with 4142 events of non-fatal myocardial infarc-
tion, 6997 of major cardiovascular events, 3517 of heart failure, 6849 of all-cause mortality, 2084 of non-fatal stroke, 
3816 of cardiovascular death were included. A 7 % reduction of major cardiovascular events was observed only when 
relatively tight glucose control resulted in a follow-up HbA1c level above 7.0 % (OR 0.93, 95 % CI 0.88–0.98; I2 = 33 %), 
however, the patients can benefit from reduction incidence of non-fatal myocardial infarction only when the follow-
up HbA1c value below 7.0 % (OR 0.85, 95 % CI 0.74–0.96). Apart from the HbA1c value above 7.0 % (OR 1.22, 95 % CI 
1.06–1.40), the application of thiazolidinediones (OR 1.39, 95 % CI 1.14–1.69) also increased the risk of heart failure, 
while the gliptins shows neutral effects to heart failure (OR 1.14, 95 % CI 0.97–1.34).
Conclusions: Relatively tight glucose control has some cardiovascular benefits. HbA1c below 7.0 % as the goal to 
maximize the cardiovascular benefits remains suspended.
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Background
Diabetes is a chronic disease, and its rapid emergence 
worldwide has led to its classification as an epidemic. The 
life expectancy of an individual who is diagnosed with 
type 2 diabetes at 40 years of age is estimated to be short-
ened by approximately 6–7  years [1]. Coronary artery 
disease accounts for 75 % of deaths in patients with dia-
betes mellitus [2–4]. Glycosylated haemoglobin (HbA1c) 
level, the most commonly used indicator of blood glucose 
level, is closely associated with cardiovascular events and 
death [5]. A 1 % point increase in HbA1c level in diabetic 
patients generates an 18 % increased risk of cardiovascu-
lar events and a 12–14 % increase in mortality [5].
Although many factors were involved in diabetic 
complications such as age, gender, systolic blood pres-
sure, and so on [6], intensive glucose control has been 
shown to reduce microvascular complications, such as 
retinopathy and nephropathy by UKPDS study [7], the 
degree to which it can reduce cardiovascular outcomes 
have been equivocal [8–10]. In ACCORD trial, a target 
HbA1c level of below 6.0 % assigned to a group subjected 
to intensive therapy, and the trial was terminated early, 
after a median of 3.5 years, because of a higher observed 
mortality rate among participants assigned to the inten-
sive therapy group [9]. Despite inconsistent results of 
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previous studies, a meta-analysis consisting of five ran-
domized controlled clinical studies, UKPDS, PROactive, 
ADVANCE, VADT and ACCORD, showed that intensive 
glycaemic control reduced the odds ratio of non-fatal 
myocardial infarction by 17 % without increasing mortal-
ity rate [11]. The American Diabetes Association recom-
mends lowering the HbA1c level below approximately 
7.0  % to reduce microvascular complications in many 
non-pregnant adults [12]. However, reducing HbA1c 
levels to below 7.0 % reduces macro-vascular complica-
tions and mortality is still unclear. An investigation of 
diabetes mellitus by the Veterans Health Administration 
reported that half of the included 205,857 patients who 
received insulin and/or sulfonylureas had HbA1c levels of 
less than 7.0  %, and these individuals were found to be 
at high risk of adverse outcomes [13]. Because determin-
ing a target HbA1c value is just a preliminary expecta-
tion, the final results of same target glycemic control vary 
widely due to the complexity of clinical practice. The cur-
rent meta-analysis assessed the effects of relatively tight 
glucose control resulting in a follow-up HbA1c level of 
below 7.0 % on a variety of cardiovascular outcomes.
Methods
Literature search strategy
We searched Medline, Web of Science and Cochrane 
Library for reports published in English between Jan 1, 
1996 and July 1, 2015 using the following search terms: 
“diabetes mellitus” in combination with the terms “cardi-
ovascular”, “macrovascular”, “complication”, and “glucose 
control”. We restricted the search to “Human species” and 
“randomized controlled trials”. A total of 6146 reports 
were further screened for inclusion by reviewing their 
titles, abstracts, or full texts. We also examined the refer-
ence lists of the identified articles previous meta-analyses 
to supplement the electronic search.
Study selection
Two independent researchers accessed the articles based 
on the following inclusion criteria: (1) randomized con-
trolled clinical trials that compared cardiovascular risk 
of intensive lowering of glucose to a standard treatment 
regimen in type 2 diabetes mellitus and (2) trials per-
formed on 1000 or more individuals with a minimum 
mean follow-up period of 1 year. Any disagreements were 
resolved by a third party or by consulting with experts. 
Twenty-three articles from 15 trials that met the inclu-
sion criteria were included in this study (Fig. 1).
Seventeen trials were excluded for the following rea-
sons: The DQDPS investigated patients with impaired 
glucose tolerance, and Leiter’s study reported out-
comes, such as glucose level and weight, but did not 
assess cardiovascular outcomes [14, 15]. The ADOPT 
study mainly evaluated the effectiveness of rosigli-
tazone on indicators of glucose metabolism and did 
not assess cardiovascular outcomes [16]. The ORIGN, 
DREAM and UGDP trials assessed outcomes in 
patients with impaired fasting glucose, impaired glu-
cose tolerance, and type 2 diabetes without separating 
them [17–19]. In the NAVIGATOR trial, pre-diabetes 
mellitus patients were treated with two drugs: valsar-
tan and/or nateglinide [20]. The Steno-2 study, Kuma-
moto Study and Veterans Affairs study included a total 
of 160, 100 and 153 diabetic patients respectively, and 
none of those studies could provide sufficient evidence 
regarding the effects of glucose control [21–23]. The 
Abstracts identified through multiple databases 
including, Medline, Cochrane Central (n=6146)
Records excluded on the basis of title and abstract
(n=6106)
Full-text articles retrieved and accessed for inclusion 
(n=40)
23 articles from 15 trials included in meta-analysis
Publication excluded from the meta-analysis (n=17)
No sufficient/suitable data to include (n=3)
Ongoing studies (n=6)
Sample size less than 170 (n=3)
Only in IGT (n=1)
IGT, IFG, T2DM were not separated (n=3)
Lifestyle intervention without drugs (n=1)
Fig. 1 Study flow chart
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LOOK-AHEAD study investigated controlling glu-
cose level with intensive lifestyle changes but did not 
record drug usage [24]. The other 6 studies that were 
excluded were still ongoing at the time of this meta-
analysis and did not have sufficient data for inclusion 
[25–30].
Data extraction
Three authors (PW, RH and SL) independently extracted 
information using standard data extraction forms 
as described in the Cochrane Handbook of System-
atic Reviews of Interventions [31]. The extracted data 
included baseline demographic characteristics, such as 
age, diabetic duration, population, BMI, and HbA1c level 
(shown in Table  1 in "Appendix"), as well as outcomes, 
including non-fatal myocardial infarction, major car-
diovascular events (cardiovascular death, non-fatal MI, 
and non-fatal stroke), all-cause mortality, cardiovascular 
death, non-fatal stroke, and heart failure. Disagreements 
were resolved by discussion with Professor SW.
Statistical analysis
Data from the 15 trials included in this meta-analysis 
were stratified according to whether patients had follow-
up HbA1c levels of <7.0 or ≥7.0 %. Odds ratios and 95 % 
CIs were calculated from dichotomous frequency data 
allocated from each trial. The I2 statistic was used to 
quantify statistical heterogeneity between trials [32]. All 
analyses were performed with a fixed-effects model when 
I2 <50 % and a randomized-effect model when I2≥ 50 % 
using Review Manager 5.0. The probability of publication 
bias was assessed by funnel plots and the Egger test [33]. 
Meta-regression analyses were used to identify the risk 
factors of heart failure between trials with Stata version 
11.0 software. All p values are two-sided; p  <0.05 was 
considered statistically significant.
Results
A total of 88,266 patients were included in this meta-
analysis: 45065 were randomized to relatively tight 
glucose control group, and 43210 were randomized 
to conventional therapy. The general baseline char-
acteristics of the participants are shown in Table 1 in 
"Appendix". The mean participant age was 63  years. 
Among the included studies, UKPDS33, UKPDS34 and 
ADDITION enrolled newly diagnosed or screened dia-
betes patients, while the participants in the other stud-
ies had a mean diabetic duration of 8 years. The mean 
follow-up period ranged from 18  months to 10  years. 
The follow-up period of DIGAMI1 ranged from 0 to 
21.8  years to observe the effect of glucose control on 
mortality in older patients who experienced myo-
cardial infarction (mean age =  68  years). Ten studies 
enrolled diabetic patients with a history of macrovas-
cular disease [9, 10, 34–41], and HEART2D, EXAMIN, 
and DIGAMI1 only enrolled patients who had recently 
experienced adverse coronary events. Most patients 
were overweight, with a mean BMI of 30  kg/m2. The 
baseline HbA1c level was 7.8 %, and the final HbA1C 
levels in the intensive glucose control and conven-
tional groups were 7.1 and 7.6  %, respectively. The 
main interventions for the relatively tight glucose con-
trol group and the conventional group are shown in 
Table 1 in "Appendix".
Outcomes of relatively tight glucose control stratified 
by follow‑up HbA1c level
Overall, relatively tight glucose control decreased the 
incidence of non-fatal myocardial infarction by 9 % (OR 
0.91, 95  % CI 0.85–0.97; I2 =  4  %; Fig.  2) and the inci-
dence of major cardiovascular events by 7  % (OR 0.93, 
95 % CI 0.89–0.97; I2 = 9 %; Fig. 3). Furthermore, major 
cardiovascular events were decreased by 7  % (OR 0.93, 
95 % CI 0.88–0.98; I2 = 33 %) when the follow-up HbA1c 
level was higher than 7.0 %, however, only when the fol-
low-up HbA1c level was lower than 7.0 %, the benefit of 
relatively tight glucose control in regards to the preven-
tion of non-fatal myocardial infarction was gained (OR 
0.85, 95 % CI 0.74–0.96; I2 = 0 %).
There was also a 17 % increase in the incidence of heart 
failure (OR 1.17, 95  % CI 1.04–1.31; I2  =  58  %; Fig.  4) 
in the relatively tight glucose control group compared 
to conventional group. The subgroup with a follow-up 
HbA1c level above 7.0 % showed an increased incidence 
of heart failure of 22  % (OR 1.22, 95  % CI 1.06–1.40; 
I2 = 57 %), while the subgroup with a follow-up HbA1c 
level below 7.0 % showed no increase in the incidence of 
heart failure (OR 1.03, 95 % CI 0.86–1.23; I2 = 38 %).
Regardless of whether the follow-up HbA1c level was 
below or above 7.0  %, no differences between the rela-
tively tight glucose control and conventional groups were 
found for all-cause mortality (OR 0.97, 95  % CI 0.90–
1.04; I2 = 20 %; Fig. 5), non-fatal stroke (OR 0.92, 95 % CI 
0.84–1.02; I2 = 9 %; Fig. 6) or cardiovascular death (OR 
1.00, 95 % CI 0.90–1.11; I2 = 48 %; Fig. 7).
The funnel plot and Egger test results showed no 
underlying publication bias.
Meta‑regression analysis and stratification according 
to relevant factors
In an attempt to determine other sources of surplus 
nuances among the trials, meta-regression analyses of 
the glucose-lowering strategies for the relatively tight 
glucose control group, history of cardiovascular dis-
ease, follow-up period, BMI, age and diabetic duration 
were performed. Among these variables, the correlation 
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between non-fatal myocardial infarction and relatively 
tight glucose control was stronger in patients with a 
BMI higher than 30 kg/m2 (OR 0.89, 95 % CI 0.82–0.96; 
I2 = 1.4 %; Table 2 in "Appendix"). In addition to a fol-
low-up HbA1c level above 7 %, the application of thia-
zolidinediones (TZDs) (OR 1.39, 95  % CI 1.14–1.69, 
I2  =  59.2  %) increased the risk of heart failure, while 
the dipeptidyl peptidase inhibitors (gliptins) shows 
neutral effects to heart failure (OR 1.14, 95 % CI 0.97–
1.34, I2 = 41.9; Table 3 in "Appendix").
Furthermore, with each 1  % decrease in HbA1c level 
between trials associated with a marginal 2  % increase 
in major cardiovascular events (OR 0.98, 95 % CI 0.82–
1.05; Fig.  8), without decrease in non-fatal myocardial 
infarction (OR 1.12, 95 % CI 0.96–1.31; Fig. 9).The mean 
HbA1c change of HbA1c below 7 % subgroup was 1.3 %, 
and in the HbA1c above 7  % subgroup was 0.3  %, with 
each 1 % increase in HbA1c change associated with mar-
ginal 7 % decrease in non-fatal myocardial infarction (OR 
0.93, 95 % CI 0.82–1.05; Fig. 10), limited association were 
found between HbA1c change and major cardiovascular 
events (OR 1.02, 95 % CI 0.93–1.13; Fig. 11). 
Discussion
The results of the current meta-analysis were consistent 
with previous studies and showed that relatively tight 
glucose control in type 2 diabetes mellitus patients has 
cardiovascular benefits, namely reducing the incidences 
of non-fatal myocardial infarction and major cardiovas-
cular events without increasing all-cause mortality. Inter-
estingly, when the follow-up HbA1c level was above 
7.0 %, the incidence of major cardiovascular events was 
obviously decreased, but the benefits in regard to the 
prevention of non-fatal myocardial infarction only can 
be obtained when the follow-up HbA1c level was below 
7.0  %. Each 1  % decrease in HbA1c level are associated 
with a marginal 2  % increase in major cardiovascular 
events, and each marginal 7 % decrease in non-fatal myo-
cardial infarction are at a cost of 1 % increase in HbA1c 
change. In spite of the HbA1c level, the increased risk of 
Fig. 2 Risk of non-fatal myocardial infarction stratified by HbA1c level of 7.0 %
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heart failure was closely associated with the application 
of thiazolidinediones, not gliptins.
Though the ACCORD [9] trial was stopped because of 
the high incidence of cardiovascular outcomes, but the 
latter ADVANCE [10] trial and meta-analysis suggested 
tight glucose control can lead to an obvious cardiovas-
cular benefits especially non-fatal myocardial infarction 
[11]. And about half of the patients who were receiving 
hypoglycemic therapy had a HbA1c level of less than 
7.0  % in the recent investigation [13]. Our study elabo-
rate the effects of glycemic control on cardiovascular out-
comes from the results of glycemic control which is the 
follow-up of HbA1c, and our study found that the inci-
dence of major cardiovascular events, including non-fatal 
stroke, non-fatal myocardial infarction and cardiovascu-
lar death were not decreased in the patients of HbA1c 
controlled below 7  % compared to the group of HbA1c 
above 7  %, though the incidence of non-fatal myocar-
dial infarction was reduced when the HbA1c level were 
controlled below 7  %. Based on the above findings, we 
inferred that strict glycaemic control targeting a follow-
up HbA1c level below 7.0 % may increase the risk of non-
fatal stroke and cardiovascular death; however, a separate 
analysis in the current study displayed no increased risk 
of non-fatal stroke or cardiovascular death. To obtain 
better blood glucose control, additional glucose lowering 
drugs must inevitably be used, thus, leading to redun-
dant weight gain and severe hypoglycaemia, which both 
increased the risk of acute diabetic complications and 
likely offset the reduced incidence of myocardial infarc-
tion that follows intensive therapy [42]. Additionally, our 
analysis also showed that to obtain non-fatal myocardial 
infarction benefits by glucose control are at a great cost of 
the HbA1c level change. In our clinical practice, the ulti-
mate goal of strict glycaemic control is to reduce diabetic 
complications and the incidence of fatal events and to 
increase the patient survival rate, not just once or twice 
reduced incidence of nonfatal myocardial infarction [43]. 
Fig. 3 Risk of major cardiovascular events stratified by HbA1c level of 7.0 %
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Taken together, a follow-up HbA1c level of 7.0  % is the 
critical control point for intensive therapy; our study sug-
gests that controlling HbA1c below 7.0 % could not maxi-
mize the cardiovascular benefits, and the disadvantages 
outweigh the advantages.
Although there was some heterogeneity across the 
included studies, the results of this meta-analysis indi-
cate that glucose control increases the risk of heart fail-
ure, and the subgroup with a follow-up HbA1c above 
7.0 % have a greater risk of heart failure. Previous studies 
have demonstrated that every percentage point increase 
in HbA1c level results in a 15  % increase in the risk of 
congestive heart failure [44]. Advanced glycation end-
products, oxidative stress and altered myocardial metab-
olism are probably involved in systolic and diastolic 
dysfunction and eventually cause heart failure, especially 
among diabetic patients with a history of heart disease 
[45–48]. Additionally, hyperglycaemia induces insulin 
secretion, which can increase the preload of the heart 
and decrease cardiac output [49]. Furthermore, elevated 
levels of glucose and insulin in the blood can activate the 
sympathetic nervous system, which has been implicated 
in the development of heart failure [50]. In addition, our 
meta-regression analysis further showed that the strate-
gies of intensive therapy are closely associated with heart 
failure, especially among patients taking PPAR agonists. 
PPAR agonists cause fluid retention and diastolic dys-
function in susceptible patients and result in haemody-
namic consequences that can cause heart failure [51]. It 
is worth pointing out that not the same with the recent 
meta-analysis which showed that gliptins induce heart 
failure in diabetic patients and patients at risk of develop-
ing T2DM [52], our study shows the effects of gliptins on 
heart failure is neutral.
This study had the inherent limitations of any meta-
analysis that results from the use of published data, 
including the absence of standardization in study 
design, duration of follow-up, strategy of intensive 
Fig. 4 Risk of heart failure stratified by HbA1c level of 7.0 %
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glycaemic control, characteristics of the study popula-
tions, and end-point definitions. Another limitation was 
the search strategies used, which could have generated 
publication bias, leading to a misinterpretation of the 
results. Fortunately, the trials included in this analysis 
were mostly large-scale clinical trials with low hetero-
geneity, which effectively avoided the inaccurate results 
that can be generated by studies with small sample 
sizes. Additionally, ADDITION did not record infor-
mation related to heart failure, so our analysis of that 
variable was based on incomplete data. Another point 
need to be considered is the choice of the indicator of 
glucose control. The mean HbA1c level and HbA1c 
change were used in this study, but the marginal value 
of the results suggested mean HbA1c level may not be 
a sensitive predictor for cardiovascular complication of 
diabetes mellitus. Other HbA1c index such as HbA1c 
variability especially intra-individual mean (HbA1c-
MEAN) or haemoglobin glycation index which showed 
a better association with cardiovascular risk in diabetes 
may be a better index of glucose control [53, 54]. Other 
factors such as blood pressure, blood lipid, inflamma-
tory biomarkers like C-reactive protein (CRP), mono-
cyte chemotactic protein-1 (MCP1) and asymmetric 
dimethyl arginine (ADMA) could also be involved in the 
development of diabetic complications and affect the 
interpretation of outcomes [55–57]. At the same time, 
recommendations regarding type 2 diabetic patients’ 
treatments have focused on personalizing HbA1c tar-
gets which could be a better solution for diabetes with 
cardiovascular complications [58]. Other interven-
tions such as lifestyle change, intensive blood pressure 
Fig. 5 Risk of all-cause mortality stratified by HbA1c level of 7.0 %
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or blood lipid control should be considered in diabetes 
mellitus [24, 59].
Conclusion
This meta-analysis indicates that intensive glycaemic 
control has cardiovascular benefits and does not increase 
all-cause mortality. However, lowering the HbA1c level 
below 7.0 % does not appear to maximize the cardiovas-
cular benefits, although the risk of non-fatal myocardial 
infarction was reduced. Further research is still necessary 
to explore the different treatment regimens of diabetes 
mellitus.
Fig. 6 Risk of stroke stratified by HbA1c level of 7.0 %
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Fig. 7 Risk of cardiovascular death stratified by HbA1c of 7.0 %
Fig. 8 Odds ratio of major cardiovascular events in relation to follow-
up HbA1c level
Fig. 9 Odds ratio of myocardial infarction in relation to follow-up 
HbA1c level
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Fig. 10 Odds ratio of myocardial infarction in relation to HbA1c 
change
Fig. 11 Odds ratio of major cardiovascular events in relation to 
HbA1c change
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